Dec 17 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd said on Tuesday two doses of its experimental treatment for acute migraine were effective in reducing headaches in a large study.
The drug, vazegepant, belongs to a new class of treatments for migraine called CGRP inhibitors. (Reporting by Manojna Maddipatla in Bengaluru Editing by Saumyadeb Chakrabarty)
Our Standards: The Thomson Reuters Trust Principles.